News - Keryx Biopharmaceuticals, Daiichi Sankyo

Filter

Popular Filters

1 to 25 of 87 results

Astellas and Daiichi Sankyo share 400,000 compounds in research agreement

Astellas and Daiichi Sankyo share 400,000 compounds in research agreement

19-03-2014

Japanese drug majors Astellas Pharma and Daiichi Sankyo will form a compound library sharing partnership…

Astellas PharmaDaiichi SankyoJapanLicensingPharmaceuticalResearch

Keryx Biopharma files for EU approval of Zerenex

Keryx Biopharma files for EU approval of Zerenex

10-03-2014

US drugmaker Keryx Biopharmaceuticals has submitted a Marketing Authorization Application to the European…

EuropeKeryx BiopharmaceuticalsNephrology and HepatologyPharmaceuticalRegulationZerenex

Daiichi Sankyo unit will not hit H5N1 vaccine supply deadline

Daiichi Sankyo unit will not hit H5N1 vaccine supply deadline

10-03-2014

Japanese drug major Daiichi Sankyo has updated on the H5N1 influenza vaccine project, revealing that…

Asia-PacificDaiichi SankyoJapanPharmaceuticalProductionVaccines

Ranbaxy temporarily suspends shipments from Toansa and Dewas plants

25-02-2014

Indian drugmaker Ranbaxy Laboratories has announced in a letter to the Stock Exchange that it has temporarily…

Asia-PacificDaiichi SankyoGenericsIndiaProductionRanbaxy Laboratories

Daiichi Sankyo and UMN Pharma collaborate over norovirus vaccine

Daiichi Sankyo and UMN Pharma collaborate over norovirus vaccine

14-02-2014

Japanese drug companies Daiichi Sankyo and UMN Pharma have signed a collaborative research agreement…

Daiichi SankyoJapanLicensingPharmaceuticalResearchVaccines

Ranbaxy rises on 4th-qtr performance, but can this continue?

Ranbaxy rises on 4th-qtr performance, but can this continue?

05-02-2014

Ranbaxy Laboratories, India’s largest generic drugmaker by sales, saw its shares rise 5.6% to 340 rupees…

Daiichi SankyoFinancialGenericsRanbaxy Laboratories

Another ban by US FDA on a Ranbaxy production facility

Another ban by US FDA on a Ranbaxy production facility

24-01-2014

As if the Indian drug major has not had enough negative news from the US regulator, the US Food and Drug…

Asia-PacificDaiichi SankyoGenericsIndiaNorth AmericaProductionRanbaxy LaboratoriesRegulationUSA

Daiichi Sankyo files Savaysa for US approval; collaborates with Virtici and Celdara Medical

Daiichi Sankyo files Savaysa for US approval; collaborates with Virtici and Celdara Medical

10-01-2014

Japanese drug major Daiichi Sankyo has filed a New Drug Application for its investigational, oral, once-daily…

Cardio-vascularCeldara MedicalDaiichi SankyoedoxabanNorth AmericaPharmaceuticalRegulationResearchSavaysaUSAVirtici

Daiichi Sankyo submits edoxaban application to the EMA for stroke prevention

Daiichi Sankyo submits edoxaban application to the EMA for stroke prevention

08-01-2014

Japanese drug major Daiichi Sankyo (TYO: 4568) has submitted a Marketing Authorization Application to…

Asia-PacificCardio-vascularDaiichi SankyoedoxabanPharmaceuticalRegulation

Ranbaxy cleared to market branded generic of Aricept in Canada

Ranbaxy cleared to market branded generic of Aricept in Canada

08-01-2014

The Canadian subsidiary of Ranbaxy Laboratories has received approval to manufacture and market RAN-Donepezil…

AriceptCanadaDaiichi SankyoEisaiGenericsNeurologicalNorth AmericaRAN-DonepezilRanbaxy LaboratoriesRegulation

Daiichi Sankyo launches Biopten Granules 10% in Japan

Daiichi Sankyo launches Biopten Granules 10% in Japan

29-11-2013

Japanese drug major Daiichi Sankyo has launched natural tetrahydrobiopterin agent Biopten Granules 10%…

Asia-PacificBioptenDaiichi SankyoMarkets & MarketingPharmaceuticalRare diseases

Daiichi Sankyo's edoxaban shows comparable efficacy to warfarin in Phase III trial

Daiichi Sankyo's edoxaban shows comparable efficacy to warfarin in Phase III trial

20-11-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) says that its blood thinner edoxaban met the primary efficacy…

Asia-PacificCardio-vascularDaiichi SankyoedoxabanPharmaceuticalResearchWarfarin Sodium

Daiichi Sankyo sales up while Ranbaxy sales decline

Daiichi Sankyo sales up while Ranbaxy sales decline

01-11-2013

Daiichi Sankyo has released results for the fiscal period April 1 to September 30, showing net sales…

Asia-PacificDaiichi SankyoFinancialPharmaceuticalRanbaxy Laboratories

US nephrologists views on prescribing Roche’s Mircera

02-10-2013

Among surveyed US nephrologists, familiarity with Swiss drug major Roche's Mircera is low, but is still…

InjectaferKeryx BiopharmaceuticalsMirceraNeurologicalNorth AmericaPharmaceuticalRocheZerenex

Daiichi Sankyo partners in new open innovation business funding

18-09-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) and Mitsubishi UFJ Capital Co have agreed to launch a…

Asia-PacificDaiichi SankyoFinancialPharmaceuticalResearch

Ban on FDA-regulated drugs from Ranbaxy's Mohali plant

17-09-2013

There was another blow for India's largest drugmaker Ranbaxy Laboratories (BSE: 500359) yesterday (September…

Asia-PacificDaiichi SankyoGenericsNorth AmericaProductionRanbaxy LaboratoriesRegulation

Pre-treatment with prasugrel - more risk, no benefit: ACCOAST

02-09-2013

In patients with non-ST-elevation acute coronary syndrome (NSTE- ACS), pre-treatment with the P2Y12 antagonist…

Cardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalprasugrelResearch

Positive Ph III results for Daiichi Sankyo's edoxaban in VTE

02-09-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) has released encouraging results from the global Phase…

Cardio-vascularDaiichi SankyoedoxabanLixianaPharmaceuticalResearch

Daiichi Sankyo files Ranmark to treat giant cell tumor of bone in Japan

29-08-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) has filed an application for approval in Japan to manufacture…

AmgenAsia-PacificDaiichi SankyoOncologyPharmaceuticalPraliaRanmarkRegulation

Keryx Biopharma files for US approval of Zerenex

09-08-2013

Keryx Biopharmaceuticals (Nasdaq: KERX) says it has submitted a New Drug Application to the US Food and…

BiotechnologyKeryx BiopharmaceuticalsNephrology and HepatologyNorth AmericaRegulationZerenex

Daiichi Sankyo's anti-clotting drug shows promise in Ph III CAD study

14-07-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) presented positive results of the PRASFIT-Elective Phase…

Cardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalprasugrelResearch

Vifor Pharma's IV Ferinject reduces the need for further anemia treatment in kidney disease patients

10-07-2013

Switzerland-based Vifor Pharma, part of the Galenica group (SIX: GALN), has announced results which show…

Daiichi SankyoEuropeFerinjectInjectaferNephrology and HepatologyPharmaceuticalVifor Pharma

Germany's Saltigo to manufacture novel drug pipeline product for Daiichi Sankyo

08-07-2013

German custom manufacturing specialist Saltigo GmbH, a subsidiary of Lanxess (Xetra: LXS), has signed…

Daiichi SankyoLanxessPharmaceuticalProductionSaltigo GmbH

Japan vaccines briefs: Gardasil and Cervarix; Daiichi Sankyo files NDA

21-06-2013

The Japanese Ministry of Health, Labor and Welfare has decided to withdraw its recommendation for a vaccination…

Asia-PacificCervarixDaiichi SankyoGardasilGlaxoSmithKlineMerck & CoPharmaceuticalRegulationVaccinesWomen's Health

1 to 25 of 87 results

Company Spotlight

Fibrotech

Fibrotech

Back to top